Our CD19-TRAIL construct may help to overcome this challenge by binding CD19+ cells and concomitantly crosslinking TRAIL receptors on neighboring tumor cells, thereby inducing apoptosis in these cells irrespective of CD19 expression (“bystander killing”) [67]. This evidence concerns the gene TNFSF10 and neoplasm.